Indivior is a pharmaceutical company specialising in addiction treatment. Indivior was spun out of parent Reckitt Benckiser in December 2014. Adding to its Suboxone opioid addiction product, the company has a pipeline including longer-lasting 'depot' formulations, treatments for cocaine intoxication, alcohol addiction and even schizophrenia, as a psychiatric co-morbidity of addiction.
Registrars:
Key Personnel
CEO:
Mark Crossley
Chairman:
David E. Wheadon
Senior Independent Director:
Juliet Thompson
Independent Non-Executive Director:
Keith Humphreys, Jo Le Couilliard, Mark Stejbach, Joe Ciaffoni, Peter Bains, Barbara Ryan, Daniel A. Ninivaggi